ChenAn Biotech Launches 'Qingyun Initiative' to Advance Innovation in Life Sciences with Single-Cell Mass Cytometry Technology

Source: DeepTech

On July 3, Polaris Biology officially launched the “Qingyun Initiative” Polaris Biology Scientific Research Collaboration Fund at the 8th CMI Symposium of the Chinese Society for Immunology.

This program is designed for biotechnology experts, research scholars, and clinical research teams, providing R&D funding of RMB 5 million and cutting-edge single-cell technology solutions to support scientific research and innovative discoveries. It aims to jointly promote original innovation in China’s life sciences sector and expand the frontiers of our understanding of life.

(Source: Polaris Biology)

Single-cell technology is one of the most disruptive and milestone breakthroughs in life science in recent years. It has deepened human understanding of organisms to the single-cell level, fundamentally changing the historical limitation of obtaining only average signal expression from cell populations, and significantly improving the resolution and accuracy of cellular detection.

Mass Cytometry is currently one of the most advanced single-cell multiparametric analysis technologies.

Mass cytometry is a flow cytometry technique that employs mass spectrometry principles for multiparametric single-cell analysis. It inherits the high-throughput analytical capabilities of conventional flow cytometry while leveraging the high-resolution detection of time-of-flight mass spectrometry. This technology liberates researchers from the constraints of fluorophore selection and compensation procedures, delivering qualitative improvements in both detection dimensionality and resolution.

Figure | Principle of Mass Cytometry Technology (Source: Polaris Biology)

In 2011, mass cytometry was named the “most-watched single-cell technology” by *Nature Methods*; that same year, it was also recognized as one of the “Top 10 Scientific Innovations of the Year” by *The Scientist* magazine.

Mass cytometry, characterized by its high-dimensional and high-precision capabilities, is a powerful tool for deciphering the complex immune system.This technology holds immense potential for application in multiple fields, including hematologic diseases, tumor immunotherapy, stem cell translational research, and the development of related therapeutics. Its robust technical advantages position mass cytometry with broad prospects for the development of diagnostic products.

The U.S. National Cancer Institute included it in its guidelines for clinical trials of cancer immunotherapies in 2018. Today, the top ten pharmaceutical companies worldwide have all begun using mass cytometry for companion diagnostic evaluation and the development of innovative therapies.

(Source: Polaris Biology)

“Qingyun Initiative” was launched by Polaris Biology, one of the few companies worldwide that has mastered core mass cytometry technology.The company has established a multidisciplinary R&D team, bringing together top-tier talent in immunology, chemistry, engineering sciences, information sciences, artificial intelligence, and other fields. Its research and development efforts span engineering innovation, clinical applications, and algorithm development.

(Source: Polaris Biology)

Currently, Polaris Biology has independently developed China’s first mass cytometry instrument, establishing a comprehensive technology platform that includes instruments, reagents, and high-dimensional data visualization and analysis suites. The company is committed to leveraging cutting-edge products and comprehensive services to empower scientists in unraveling the complexity of diseases and addressing biological challenges.

At the 8th CMI International Immunology Symposium, Dr. Wang Xinzhu, Vice President of Polaris Biology, announced the launch of the “Qingyun Initiative” Polaris Biology Scientific Research Collaboration Fund, to support Chinese scientists in their exploratory innovations in the field of immunology.

(Source: Polaris Biology)

At the practical level, the “Qingyun Initiative” plans to select 10 research projects, for which Polaris Biology will provide free single-cell technology support and single-cell data bioinformatics analysis services.

(Source: Polaris Biology)

The driving force of life sciences stems from underlying analytical technologies; every advancement in cognitive tools brings forth new insights. In elucidating complex biological processes, Polaris Biology leverages foundational technologies to support source innovation in the life sciences industry.

Polaris Biology, established in 2016, specializes in the research and development of precision diagnostic technologies at the single-cell level and their clinical applications.

Polaris Biology has developed China’s first mass cytometry instrument, offering an integrated, end-to-end solution that includes hardware,配套 reagent kits, and high-dimensional data visualization and analysis software. Currently, the company’s mass cytometry technology has been applied in fields such as tumor immunology, infectious disease immunology, autoimmunity, neuroinflammation, and T-cell antigen discovery.

“Qingyun Initiative” is a mass cytometry research collaboration fund launched by Polaris Biology on July 3, 2021, with a total budget of RMB 5 million. The initiative aims to further explore the application potential of single-cell technologies and facilitate original innovative discoveries in the field of life sciences.

Polaris Biology commits to maintaining the confidentiality of all submitted project plans. Polaris Biology reserves the final right of interpretation for this event.